Orchid Pharma new antibiotic drug gets EMA approval; stock surges 20%
‘Exblifep’ obtained marketing authorisation from the EMA for the treatment of complex urinary tract infections, pneumonia, and bacteremia caused by ESBL-producing pathogens.
orchid pharma company
January 2024
June 2023
December 2022
Orchid Pharma shares hit 52-week high on raising ₹400 cr via QIP
Investors who have been allotted over 5% equity shares are MIT (23.75%), Quant’s Multi-Asset Fund (12.75%) and Value Fund (6.75%), Carnelian Structural Shift Fund (6.25%) and Societe Generale (6%)
Orchid Pharma shares gain 3% on board’s nod to raise ₹500 cr via QIP
Orchid Pharma stock trades 12% lower than its 52-week high of ₹463.05, while it has surged 56% against its 52-week low of ₹260.20.
